£1.94m
vs Mar 2025Active15734758Private limited companyLondon
NUCLIDE THERAPEUTICS LTD
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for Nuclide Therapeutics Ltd: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
Coming soon · product and service lists
What does Nuclide Therapeutics Ltd sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
One email, only about this. If we don’t launch within 60 days we’ll tell you. Privacy
01
Summary
NUCLIDE THERAPEUTICS LTD is an active private limited company (company number 15734758) incorporated on 22 May 2024, registered in London. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest small accounts cover the period ending 31 March 2026, showing net assets of £1.94m and cash of £1.93m, with 3 employees on average. Net assets rose 1121917% on the prior period (−£173).
Peer position · net assets
By net assets it sits in the top quarter of 603 comparable companies in London (median £440, upper quartile £92k).
02
Ownership and control
No active person with significant control is registered.
- Dr Timothy Howard Witney
- owns 25–50% of shares
- holds 25–50% of voting rights
- can appoint or remove directors
- Dr Richard Sherburne Edwards
- owns 25–50% of shares
- holds 25–50% of voting rights
- can appoint or remove directors
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
03
Key dates
- Incorporated
- 22 May 20242 yrs ago
- Next accounts due
- 31 December 2027in 432 days
- Confirmation statement due
- 5 June 2027in 223 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
04
Activity
- SIC 72110
- Research and experimental development on biotechnology
- Accounts type
- Total Exemption Full
- Size band
- MicroCompanies Act thresholds
05
Financials
£1.93m
+7435215%vs Mar 2025Not reported
3
vs Mar 2025| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 31 March 2026 | £1.94m | £1.93m | £9,038 | — | — | — | 3 |
| 31 March 2025 | −£173 | £26 | — | — | — | — | 0 |
Cash per employee£644kCash ÷ average employees
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing.
06
Filing and accounts signals
- Net assets above zeroNet assets £1,940,744 at 31 March 2026
- Net assets up 10% or more on the prior period+1121917.3% vs prior period
- Cash at bank of £50,000 or moreCash £1,933,182
- Incorporated two to five years agoIncorporated 22 May 2024
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
07
Timeline
- Next accounts duein 432 days
- Confirmation statement duein 223 days
- Accounts period endNet assets £1.94m · small accounts
- Accounts period endNet liabilities £173 · small accounts
- Incorporated
08
Similar companies in London
09
Reminders for NUCLIDE THERAPEUTICS LTD
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.